Therefore, we have developed a new method to easily determine genome-wide DNA methylation status and obtained regulatory approval for a new in vitro diagnostic that can accurately predict the sensitivity of anti-EGFR antibody drugs for advanced/recurrent CRC. Here, EGFR is linked to colorectal carcinoma.